Prothrombinase enhancement through quantitative and qualitative changes affecting very low density lipoprotein in complex with C-reactive protein

Summary

The biphasic waveform that can predict for disseminated intravascular coagulation (DIC) is due to the formation of a calcium-dependent complex between C reactive protein (CRP) and very low density lipoprotein (VLDL). As thrombin generation is pivotal to DIC, this aspect has been specifically investigated and the VLDL component has been found to increase prothrombinase activity via both quantitative and qualitative changes. The specific prothrombinase activity of VLDL from patients manifesting the biphasic waveform was 2.5 times that of normal individuals or critically ill patients without the biphasic waveform. This activity was due to an increase in anionic phospholipid surfaces that could be inhibited with excess annexin V and which was dependent on structurally intact apolipoprotein B.The qualitative change appeared to be due to a deficiency of phosphatidylethanolamine inVLDL from patients with the biphasic waveform.The functional consequence of this enhanced prothrombinase activity was an increased procoagulant effect in plasma. Using a modified activated partial thromboplastin time assay, the mean normal clot time decreased significantly when VLDL from patients with biphasic waveforms was substituted.These results indicate that VLDL derived from patients with the biphasic waveform can enhance thrombin procoagulant activity. As the CRP-VLDL complex exists in vivo, it could have a pathogenic role in disseminating the process of intravascular coagulation.

Keywords

DIC - lipoproteins - phospholipids - thrombin - sepsis

• References

• 1 Toh CH, Samis J, Downey C. et al. The biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca++-induced complex of C-reactive protein with very low density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 2002; 100: 2522-9.
• 2 Downey C, Kazmi R, Toh CH. Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation. Br J Haematol 1997; 98: 68-73.
• 3 Downey C, Kazmi R, Toh CH. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Thromb Haemost 1998; 80: 65-9.
• 4 Toh CH, Ticknor LO, Downey C. et al. Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Intensive Care Med 2003; 29: 55-61.
• 5 Rowe IF, Soutar A, Trayner IM. et al. Circulating human C-reactive protein binds very low density lipoproteins. Clin Exp Immunol 1984; 58: 237-44.
• 6 Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
• 7 Giles AR, Nesheim ME, Mann KG. Studies of factors V and VIII: C in an animal model of disseminated intravascular coagulation. J Clin Invest 1984; 74: 2219-25.
• 8 Gando S, Nanzaki S, Sasaki S. et al. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998; 79: 1111-5.
• 9 Mann K, Nesheim M, Church W. et al. Surface dependent reactions of the vitamin K dependent enzyme complexes. Blood 1990; 76: 1-16.
• 10 Bouchard BA, Catcher CS, Thrash BR. et al. Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. J Biol Chem 1997; 272: 9244-51.
• 11 Tracy PB, Robinson RA, Worfolk LA. et al. Procoagulant activities expressed by peripheral blood mononuclear cells. Methods Enzymol 1993; 222: 281-99.
• 12 Moyer MP, Tracy RP, Tracy PB. et al. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol 1998; 18: 458-65.
• 13 Rota S, McWilliam NA, Baglin TP. et al. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood 1998; 91: 508-15.
• 14 Pepys MB, Berger A. The renaissance of C reactive protein. BMJ 2001; 322: 4-5.
• 15 Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res 1989; 30: 39-49.
• 16 Taylor FB, Toh CH, Hoots WK. et al. Towards definition, clinical and laboratory criteria and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-30.
• 17 Brufatto N, Nesheim ME. The use of prothrombin (S525C) labelled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation. J Biol Chem 2001; 276: 17663-71.
• 18 Vitiello F, Zanetta JP. Thin-layer chromatography of phospholipids. J Chromatogr 1978; 166: 637-40.
• 19 Meers P, Mealy T. Calcium-dependent annexin V binding to phospholipids: stoichiometry, specificity, and the role of negative charge. Biochemistry 1993; 32: 11711-21.
• 20 Tait JF, Gibson D. Phospholipid binding of annexin V: effects of calcium and membrane phosphatidylserine content. Arch Biochem Biophys 1992; 298: 187-91.
• 21 Zhang BH, Hornsfield BP, Farrell GC. Chronic ethanol administration to rats decrea-ses receptor-operated mobilization of intracellular ionic calcium in cultured hepatocytes and inhibits 1,4,5-inositol triphosphate production: relevance to impaired liver generation. J Clin Invest 1996; 98: 1237-44.
• 22 Sung YJ, Sung Z, Ho CL. et al. Intercellular calcium waves mediate preferential cell growth toward the wound edge in polarized hepatic cells. Exp Cell Res 2003; 287: 209-18.
• 23 Reddy NM, Hall SW, MacKintosh FR. Partial thromboplastin time: prediction of adverse events and poor prognosis by low abnormal values. Arch Intern Med 1999; 159: 2706-10.
• 24 Deguchi H, Fernandez JA, Hackeng TM. et al. Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci USA 2000; 97: 1743-48.
• 25 Higgins DL, Callahan PJ, Prendergast FG. et al. Lipid mobility in the assembly and expression of the activity of the prothrombinase complex. J Biol Chem 1985; 260: 3604-12.
• 26 Galan AM, Hernandez MR, Bozzo J. et al. Preparations of synthetic phospholipids promote procoagulant activity on damaged vessels: studies under flow conditions. Transfusion 1998; 38: 1004-10.
• 27 Rosing J, Speijer H, Zwaal RF. Prothrombin activation on phospholipid membranes with positive electrostatic potential. Biochemistry 1988; 27: 8-11.
• 28 Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-19.
• 29 Griffin JH, Kojima K, Banka CL. et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103: 219-27.
• 30 Smirnov MD, Triplett DT, Comp PC. et al. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 309-16.
• 31 Falls LA, Furie B, Furie BC. Role of phosphatidylethanolamine in assembly and function of the factor IXa-factor VIIIa complex on membrane surfaces. Biochemistry 2000; 39: 13216-22.
• 32 Smirnov MD, Ford DA, Esmon CT. et al. The effect of membrane composition on the hemostatic balance. Biochemistry 1999; 38: 3591-98.
• 33 Hasty AH, Linton MF, Swift LL. et al. Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance. J Lipid Res 1999; 40: 1529-38.
• 34 Klein S, Spannagl M, Engelmann B. Phosphatidylethanolamine participates in the stimulation of the contact system of coagulation by very-low-density-lipoprotein. Arterioscler Tromb Vasc Biol 2001; 21: 1695-70.
• 35 Gordon BR, Parker TS, Levine DM. et al. Low lipid concentrations in critical illness: implications for preventing and treating endotoxaemia. Crit Care Med 1996; 24: 584-9.